412293-42-6

Basic information

• Product Name: 8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid
• Synonyms: 8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid;1,4-Dioxaspiro[4.5]decane-8-carboxylicacid,8-methyl-
• CAS NO: 412293-42-6
• Molecular Formula: C₁₀H₁₆O₄
• Molecular Weight: 200.23164
• EINECS: -0
• Mol File: 412293-42-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid(412293-42-6)
• EPA Substance Registry System: 8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid(412293-42-6)

Safety Data

• Hazardous Substances Data: 412293-42-6(Hazardous Substances Data)

Usage

General Description

8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid is a chemical compound with the molecular formula C11H18O4. It is a carboxylic acid derivative with a spiro ring structure containing a dioxane moiety. 8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid is a white crystalline solid and is insoluble in water but soluble in organic solvents. It is commonly used in organic synthesis and pharmaceutical research as a building block for the development of new drugs. The spiro ring structure of 8-Methyl-1,4-dioxaspiro[4.5]decane-8-carboxylic acid gives it unique properties and it has potential applications in the field of medicinal chemistry.

Upstream product

• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 87787-08-4 methyl 4,4-ethylenedioxy-1-methylcyclohexanecarboxylate 
• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1523-89-3 methyl 1-methyl-4-oxo-2-cyclohexene-1-carboxylate 
• 37480-41-4 methyl 1-methyl-4-oxo-1-cyclohexanecarboxylate 
• 107-21-1 ethylene glycol 
• 24730-88-9 ethyl 8-methyl-1,4-dioxa-spiro[4.5]decane-8-carboxylate 

Downstream Products

• 87787-22-2 4-(8-Methyl-1,4-dioxa-spiro[4.5]dec-8-ylmethoxy)-phenylamine 
• 87787-16-4 4-(4,4-ethylenedioxy-1-methylcyclohexylmethoxy)nitrobenzene 
• 886615-91-4 (8-methyl-1,4-dioxa-spiro[4,5]dec-8-yl)-carbamic acid benzyl ester 
• 87787-08-4 methyl 4,4-ethylenedioxy-1-methylcyclohexanecarboxylate 
• 37480-40-3 methyl 4,4-dimethoxy-1-methylcyclohexanecarboxylate 
• 1207111-50-9 4-((tert-butyldimethylsilyloxy)methyl)-4-methylcyclohexanone 
• 1557246-64-6 (4,4-dimethoxy-1-methylcyclohexyl)methanol 
• 24730-90-3 4-(hydroxymethyl)-4-methylcyclohexanone 
• 1557249-05-4 C₃₂H₅₁N₅O₃Si₂ 
• 1557232-69-5 (6S)-N-(1-benzyl-1H-pyrazol-4-yl)-6-(hydroxymethyl)-6-methyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide 
• 1557232-67-3 (6R)-N-(1-benzyl-1H-pyrazol-4-yl)-6-(hydroxymethyl)-6-methyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide 
• 24463-41-0 1-methyl-4-oxo-cyclohexanecarboxylic acid 

Relevant articles and documents

2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF

The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS

The present invention provides compounds of the formula below (I'): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.

NITROGENOUS FIVE-MEMBERED RING COMPOUNDS

The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I] : wherein symbols in the formula have the following meanings;A: -CH2- or -S-,B: CH or N,R1: H, a lower alkyl group, etc.,X: a single bonding arm, -CO-, -Alk-CO-, -COCH2-, -Alk-O-, -O-CH2-, -SO2-, -S-, -COO-, -CON(R3)-, -Alk-CON(R3)-, -CON(R3)CH2-, -NHCH2-, etc.,R3: hydrogen atom or a lower alkyl group,Alk: a lower alkylene group, andR2: (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is -CO-, then B is N, or a pharmaceutically acceptable salt thereof.